Sweegen’s Rebaudioside M receives full authorization for use in the United Kingdom

Bestevia Reb M expands sugar reduction solutions in the U.K.and is now available to food and beverage producers.

Rancho Santa Margarita, Calif., May 17, 2023 (GLOBE NEWSWIRE) — Global sweetness and flavor innovator, Sweegen has announced that its Bestevia® Rebaudioside M (Reb M) has been fully authorized for use in the United Kingdom (U.K.) This regulatory approval marks a significant milestone for Sweegen, as it becomes the first and only company to receive authorization for any steviol glycosides produced using alternative technologies in the U.K.

Reb M, a high-purity steviol glycoside derived from the stevia plant, is renowned for its clean and sugar-like taste profile. It offers a natural, zero-calorie sweetness solution, making it an ideal choice for food and beverage manufacturers seeking to reduce sugar content and provide healthier options to consumers. Sweegen’s nature-based sweeteners, including its Reb M, offer a scalable and cost-effective alternative to traditional sugar.

Brands in the U.K. have eagerly anticipated the authorization of Sweegen’s Bestevia Reb M during the initial formulation phase and tastings. They are actively collaborating with Sweegen’s food and beverage applications experts based at its EMEA U.K. Innovation Studio in Reading, England, to integrate this highly sought-after stevia ingredient, along with Sweegen’s outstanding taste modulation and unique sweeteners, into their formulations.

Damian Bellusci, Vice President of Sales EMEA/APAC at Sweegen, expressed his excitement about the authorization, stating, “We are extremely proud to be the pioneers in securing full authorization for Bestevia Reb M in the U.K. This milestone reaffirms Sweegen’s commitment to providing innovative, nature-based, and sustainable sweetening solutions to the industry. Reb M offers food and beverage manufacturers an exceptional tool to meet consumer demands for healthier products without compromising taste.”

The decision to authorize the bioconversion manufacturing method for steviol glycosides, including Reb M, was made by the Minister for Primary Care and Public Health in relation to England, the Welsh Ministers in relation to Wales, and the Minister for Public Health, Women’s Health and Sport in relation to Scotland. The authorization is per Article 10(1) of retained Regulation 1333/2008, fulfilling the requirements.

The authorized manufacturing method allows for using steviol glycosides, including Reb M, in the Great Britain (GB) market. The Regulations provide updated terms of authorization for using this method in GB, with the terms being similar to those in the European Union (EU) and Northern Ireland. For the latest information, referring to the relevant EU Regulations on the EUR-Lex website is recommended.

Casey McCormick, Vice President of Global Innovation at Sweegen, emphasized the significance of Reb M in driving product innovation. “The approval of Bestevia Reb M in the UK represents a very positive step forward for brands looking to improve the nutrition profile of their products. The clean, sweet taste of our Bestevia Reb M enables new approaches to reduce and eliminate sugar in a way that exceeds consumers’ expectations  and supports public health objectives to reduce sugar consumption.”

Hadi Omrani, Vice President of Technical and Regulatory Affairs at Sweegen, highlighted the rigorous safety and compliance standards behind Bestevia Reb M’s authorization. Omrani stated, “At Sweegen, we prioritize safety, quality, and regulatory compliance. Obtaining full authorization for Bestevia Reb M in the U.K. required thorough scientific evaluations and stringent assessments to ensure its safety for consumption. This achievement reflects our commitment to delivering superior products that meet the highest industry standards.”

Sweegen is dedicated to revolutionizing the sweetener market with innovative solutions that promote healthier choices without compromising taste. The full authorization of Bestevia Reb M in the U.K. reinforces Sweegen’s leadership in the nature-based sweetener space and positions the company as a trusted partner for food and beverage manufacturers worldwide.

Sweegen recently attained FEMA GRAS status for sweet proteins brazzein and thaumatin II, complementing steviol glycosides in food and beverage production. With the addition of brazzein and thaumatin II, Sweegen continues to expand its portfolio of safe and effective taste-modulating flavors that can help food and beverage manufacturers meet the demand for healthier and delicious products to align with consumers’ holistic approaches to wellness. Brazzein is the star ingredient in Sweegen’s newly launched Sweetensify flavors for taste modulation, an ideal flavors tool for brands seeking to create sugar-like tastes in food and beverages.

About Sweegen

Sweegen provides sweet-taste solutions for food and beverage manufacturers around the world.
We are on a mission to reduce sugar and artificial sweeteners in the global diet. Partnering with customers, we create delicious zero-sugar products that consumers love. With the best modern sweeteners in our portfolio, such as Bestevia® Rebs B, D, E, I, M, and N, and sweet proteins brazzein and thaumatin, along with our deep knowledge of flavor modulators and texturants, Sweegen delivers market-leading solutions that customers want, and consumers prefer. Well. Into the Future.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1996. Sweegen’s actual results may differ from the estimates, assumptions, and other illustrative material contained herein, and consequently, a reader should not rely on these forward-looking statements as predictions of future events. These forward-looking statements include, without limitation, illustrative information regarding Sweegen’s bottom-up assumed market potential, assumed hit rate, and the resulting revenue based on these model inputs. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Industry, Market, and Other Data
In this press release, we rely on and refer to information and statistics regarding market participants in the sectors in which Sweegen competes and other data. We obtained this information and statistics from our own internal estimates and third-party sources, including reports by market research firms and company filings. We do not expressly refer to these sources. All of this information involves a number of assumptions and limitations, and the sources of such information cannot guarantee the accuracy or completeness of such information. The industry in which Sweegen operates is subject to a high degree of uncertainty and risk due to a variety of important factors, any of which could cause results to differ materially from those expressed in the estimates made by Sweegen or third parties.

Cautionary Statement Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener, brazzein, and thaumatin. These statements are based on current expectations but are subject to certain risks and uncertainties, many of which are difficult to predict and beyond Sweegen’s control.

Relevant risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements and, therefore, should be carefully considered. Sweegen assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.

Attachments

Ana Arakelian
Sweegen
+1.949.709.0583
ana.arakelian@sweegen.com

GlobeNewswire Distribution ID 8841398

Philips announces exchange ratio for 2022 dividend

May 17, 2023

Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend for the year 2022 is 1 new common share for every 22.3906 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 11, 12 and 15, 2023, of EUR 19.0020 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 39,334,938 new common shares.

Distribution of the dividend with delivery of new common shares and settlement of any fractions in cash, will take place from May 18, 2023. Upon distribution, the total issued share capital will amount to EUR 185,730,004, representing 928,650,020 common shares.

Before the end of the year, Philips expects to cancel a total of 15,134,054 shares. The shares to be cancelled include treasury shares already held and shares yet to be acquired in the course of 2023 through the settlement of forward contracts entered into as part of the EUR 1.5 billion share repurchase program for capital reduction purposes, as announced on July 26, 2021. More information is available via this link.

For further information, please contact:

Elco van Groningen
Philips Global Press Office
Tel.: +31 6 8103 9584
E-mail: elco.van.groningen@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

GlobeNewswire Distribution ID 1000810567

OTC Markets Group ต้อนรับ Techtronic Industries Co. Ltd. เข้าสู่ตลาด OTCQX

นิวยอร์ก, May 17, 2023 (GLOBE NEWSWIRE) —  OTC Markets Group Inc. (OTCQX: OTCM) ผู้ดำเนินการตลาดที่มีการควบคุมสำหรับการซื้อขายหลักทรัพย์ 12,000 U.S. และหลักทรัพย์ต่างประเทศ ได้ประกาศในวันนี้ว่า Techtronic Industries Co. Ltd. (Hong Kong Stock Exchange: 669; OTCQX: TTNDY, TTNDF) ผู้นำระดับโลกด้านเครื่องมือระดับมืออาชีพไร้สาย เครื่องมือทำด้วยตนเอง (DIY) และอุปกรณ์ไฟฟ้ากลางแจ้ง มีคุณสมบัติเหมาะสมที่จะเปิดให้มีการซื้อขายในตลาดที่ดีที่สุดบน OTCQX® ซึ่งก่อนหน้านี้ได้เปิดให้มีการซื้อขายบนตลาด Pink® หุ้นสามัญของ TTI จะยังคงเปิดให้ซื้อขายต่อไปใน The Stock Exchange of Hong Kong Limited (SEHK) ภายใต้รหัสหุ้น: 669

Techtronic Industries Co. Ltd. เริ่มเปิดให้มีการซื้อขายวันนี้ที่ตลาด OTCQX ภายใต้สัญลักษณ์ “TTNDY” และ “TTNDF” นักลงทุนสหรัฐฯ สามารถค้นหาการเปิดเผยข้อมูลทางการเงินในปัจจุบันและใบเสนอราคาระดับ 2 แบบเวลาจริงของบริษัทได้ที่ www.otcmarkets.com

การอัปเกรดเป็นตลาด OTCQX เป็นขั้นตอนสำคัญสำหรับบริษัทที่ต้องการเปิดให้มีการซื้อขายอย่างโปร่งใสสำหรับนักลงทุนในสหรัฐอเมริกา สำหรับบริษัทที่จดทะเบียนในการแลกเปลี่ยนระหว่างประเทศที่มีคุณสมบัติเหมาะสม มาตรฐานตลาดที่คล่องตัวจะช่วยให้บริษัทเหล่านั้นใช้ประโยชน์จากการรายงานตลาดในประเทศเพื่อให้ข้อมูลของบริษัทพร้อมใช้งานในสหรัฐอเมริกา บริษัทต่าง ๆ จะต้องมีมาตรฐานทางการเงินระดับสูง ปฏิบัติตามหลักปฏิบัติที่ดีที่สุดด้านบรรษัทภิบาล และแสดงการปฏิบัติตามกฎหมายหลักทรัพย์ที่เกี่ยวข้อง เพื่อให้มีคุณสมบัติเหมาะสมสำหรับตลาด OTCQX

คุณ Joseph Galli ประธานเจ้าหน้าที่บริหารของ TTI กล่าวว่า “เรามีความยินดีที่จะได้เริ่มเปิดให้มีการซื้อขายในตลาด OTCQX ฮ่องกงยังคงเป็นภูมิลำเนาของการจดทะเบียนแลกเปลี่ยนหลักของ TTI แต่การพัฒนาใหม่นี้จะเพิ่มสภาพคล่องให้กับทั้งหุ้นสามัญและโปรแกรม ADR ของเรามากขึ้น และในขณะเดียวกันก็ทำให้ชุมชนการลงทุนทั่วโลกเข้าถึงหุ้นได้มากขึ้น”

Securities Law USA, PLLC ทำหน้าที่เป็นผู้สนับสนุน OTCQX ของบริษัท

เกี่ยวกับ Techtronic Industries Co. Ltd.
TTI ก่อตั้งขึ้นในปี 2528 และจดทะเบียนในตลาดหลักทรัพย์ฮ่องกงในปี 2533 เป็นผู้นำระดับโลกในด้านเทคโนโลยีไร้สาย ซึ่งครอบคลุมถึงเครื่องมือไฟฟ้า อุปกรณ์ไฟฟ้ากลางแจ้ง ผลิตภัณฑ์ดูแลพื้นและผลิตภัณฑ์ทำความสะอาดสำหรับผู้บริโภค มืออาชีพ และผู้ใช้ทางอุตสาหกรรมในบ้าน การก่อสร้าง การบำรุงรักษา อุตสาหกรรม และโครงสร้างพื้นฐาน บริษัทมีรากฐานที่สร้างขึ้นจากปัจจัยขับเคลื่อนเชิงกลยุทธ์ 4 ประการ ได้แก่ แบรนด์ที่ทรงพลัง ผลิตภัณฑ์ที่เป็นนวัตกรรม บุคลากรที่ยอดเยี่ยม และความเป็นเลิศในการดำเนินงาน ซึ่งสะท้อนให้เห็นถึงวิสัยทัศน์ที่กว้างขวางในระยะยาวเพื่อพัฒนาเทคโนโลยีไร้สายให้ก้าวหน้า กลยุทธ์การเติบโตระดับโลกของการแสวงหานวัตกรรมผลิตภัณฑ์อย่างไม่หยุดยั้งทำให้ TTI ก้าวขึ้นสู่แถวหน้าของอุตสาหกรรม ผลงานผลิตภัณฑ์แบรนด์ที่มีประสิทธิภาพของ TTI ได้แก่ เครื่องมือไฟฟ้า MILWAUKEE, RYOBI และ AEG, อุปกรณ์เสริม เครื่องมือช่างและผลิตภัณฑ์กลางแจ้ง ผลิตภัณฑ์วางผังและการวัดของ EMPIRE และ HOOVER, VAX, DIRT DEVIL และ ORECK ผลิตภัณฑ์ดูแลพื้นและทำความสะอาด

เกี่ยวกับ OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) ดำเนินการตลาดที่มีการควบคุมสำหรับการซื้อขายหลักทรัพย์ 12,000 U.S. และหลักทรัพย์ต่างประเทศ มาตรฐานการเปิดเผยที่ขับเคลื่อนด้วยข้อมูลของเรานั้นเป็นรากฐานของตลาดสาธารณะสามแห่งของเรา: OTCQX® เป็นตลาดที่ดีที่สุด OTCQB® เป็นตลาดร่วมลงทุน และ Pink® เป็นตลาดเสรี

ระบบการซื้อขายทางเลือก (ATS) OTC Link® ของเรานั้น ได้ให้บริการโครงสร้างพื้นฐานของตลาดที่สำคัญซึ่งนายหน้า-นักธุรกิจใช้พึ่งพาเพื่ออำนวยความสะดวกในการซื้อขาย รูปแบบนวัตกรรมของเราช่วยให้บริษัทต่าง ๆ เข้าถึงตลาดการเงินของสหรัฐอเมริกาได้อย่างมีประสิทธิภาพมากขึ้น

OTC Link ATS, OTC Link ECN และ OTC Link NQB ต่างก็เป็น ATS ที่อยู่ภายใต้การควบคุมของ SEC ซึ่งดำเนินการโดย OTC Link LLC ซึ่งเป็นนายหน้าผู้ค้าหลักทรัพย์ที่จดทะเบียนกับ FINRA และ SEC และเป็นสมาชิกของ SIPC

หากต้องการเรียนรู้เพิ่มเติมเกี่ยวกับวิธีที่เราสร้างตลาดที่ให้ข้อมูลดีขึ้นและมีประสิทธิภาพมากขึ้น กรุณาเยี่ยมชม www.otcmarkets.com

สมัครสมาชิก RSS Feed ของ OTC Markets

ติดต่อด้านสื่อ:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

GlobeNewswire Distribution ID 8841240

AeroSpace Power Conference celebrates 100th anniversary of armed forces with resounding success

AeroSpace Power Conference 2023 (Photo 1)

AeroSpace Power Conference 2023

Rome, May 17, 2023 – The AeroSpace Power Conference, the grand event commemorating the 100th anniversary of the Armed Forces, concluded on May 14th with remarkable achievements. Gathering an impressive participation of 1,800 attendees on each day of the event, including 41 foreign delegations and 25 heads of forces from around the globe, the conference stood as a testament to its extraordinary success. Hosted at the captivating and iconic ‘La Nuvola di Fuksas’ conference centre in Rome, this momentous occasion was organized by Pomilio Blumm, an Italy-based institutional communication agency. The company managed every aspect of the three-day event, from setting up exhibition stands to producing presentation videos and directing the online proceedings.

Over the course of three days, the AeroSpace Power Conference featured a diverse program of debates, speeches, and contributions, encompassing a total of five panels. Key discussions revolved around future challenges related to innovation and technology, comprehensive aerospace strategies and policies, as well as innovation and sustainability within the sector.

AeroSpace Power Conference 2023 (photo 2)

AeroSpace Power Conference 2023

Space and aerospace represent the natural extension of the Air Force’s operational domain, which, due to the evolution of enabling technologies and challenges, is called upon every day to defend the country from new threats, such as ballistic missiles, space debris or uncontrolled re-entries, which must be identified and tracked in space.

Among the speakers were notable academics, researchers, and both civil and military experts. Air Squadron General Luca Goretti, the Chief of Staff of the Air Force, inaugurated the conference on Friday, May 12th, in the presence of Defense Minister Guido Crosetto, Chief of Defense Staff Admiral Giuseppe Cavo Dragone, and several other authorities. Ferrari CEO Benedetto Vigna was also present. The participation of representatives from NATO, various space agencies, the European Defense Agency, LEONARDO, LUISS, and AVIO further enhanced the panels. The event also welcomed international guests, such as Gen. Hiroaki Uchikura from Japan, Air Chief Marshall Mike Wigston from the UK, and US Under Secretary of Defense Heidi Shyu.

AeroSpace Power Conference 2023 (Photo 3)

AeroSpace Power Conference 2023

Franco Pomilio expressed his pride in being part of this prestigious event commemorating the centenary of the Air Force. Pomilio Blumm curated the aerospace exhibition, which garnered significant attention and participation. The exhibition attracted an impressive registration of 12,978 individuals, allowing them to explore numerous Air Force stands, partake in enjoyable activities, engage with simulators, and attend thought-provoking film screenings on the 100 years of the Armed Force.

Attachments

GlobeNewswire Distribution ID 1000810480

Philips launches AI-powered CT system to accelerate routine radiology and high-volume screening programs

May 17, 2023

  • New Philips CT 3500 increases return on investment by meeting the throughput and uptime needs of routine radiology and high-volume screening programs
  • AI-powered workflow and image reconstruction enhance productivity and first-time-right imaging

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the Philips CT 3500, a new high-throughput CT system targeting the needs of routine radiology and high-volume screening programs. Powered by AI, the Philips CT 3500 includes a range of image-reconstruction and workflow-enhancing features that help to deliver the consistency, speed, and first-time-right image quality needed for confident diagnoses by clinicians and increased return on investment – even in the most demanding, high-volume care settings.

“Increased financial pressures, chronic staff shortages, and escalating patient demand are driving radiology departments to do everything they can to maximize throughput, to guarantee equipment uptime, and to avoid repeat scans,” said Frans Venker, General Manager Computed Tomography at Philips. “Today, many radiology departments scan hundreds of patients a day. We’ve engineered the Philips CT 3500 to reduce the pain points that these high-volume departments face by developing a versatile, reliable, high-throughput imaging solution. It automates radiographers’ most time-consuming steps so that they can spend more time focusing on the patient.”

Accelerating workflows
The CT 3500 features Philips’ latest AI-powered CT Smart Workflow to automate every step in the scanning process. Precise Position uses a camera to automatically determine patient orientation, improving positioning accuracy by 50% while reducing patient positioning time by up to 23% [1]. Precise Planning automatically determines the area to be scanned and the appropriate Exam Card based on the patient’s anatomy. This provides fast exam preparation and can improve inter-operator consistency. Precise Intervention can offer automated setup and treatment guidance for tissue biopsies and other needle-based interventions.

Delivering high-quality images at low dose
Precise Image AI-based reconstruction is designed to deliver the high image quality needed by radiologists to make a precise diagnosis. Precise Image allows radiology departments to simultaneously achieve up to 60% improved low-contrast detectability, 85% lower noise, and 80% lower radiation dose. All reference protocols are reconstructed in under a minute to support even the busiest radiology departments [2,3].

Boosting up-time
The CT 3500 is designed to deliver the uninterrupted imaging required by high-throughput radiology departments and screening programs including mobile screening units. To achieve this level of reliability, the CT 3500 is built on Philips’ highly regarded vMRC tube and tracks critical performance metrics with internal and external proactive monitoring sensors that allow Philips service engineers to intervene prior to any potential impact on CT operations.

Adding to Philips’ existing portfolio of high-performance CT solutions, the CT 3500 is being launched back-to-back at the 2023 China International Medical Equipment Fair (CMEF 2023, May 14 – 17, Shanghai, China) and the 2023 Deutscher Röntgenkongress (ROKO 2023, May 17 -19, Wiesbaden, Germany).

[1] Based on Philips in-house assessment by five clinical experts, comparing manual versus Precise Positioning in 40 clinical cases using a human body phantom. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[2] In clinical practice, the use of Precise Image may reduce CT patient dose depending on the clinical task, patient size, and anatomical location. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Dose reduction assessments were performed using reference body protocols with 1.0 mm slices at the “Smoother” setting of Precise Image, and tested on the MITA CT IQ Phantom (CCT189, The Phantom Laboratory) assessing the 10 mm pin and compared to filtered-back projection. A range is seen across the 4 pins, using a channelized hoteling observer tool, that includes lower image noise by 85% and improved low-contrast detectability from 0% to 60% at 50% to 80% dose reduction. NPS curve shift is used to evaluate image appearance, as measured on a 20 cm water phantom in the center 50 mm x 50 mm region of interest, with an average shift of 6% or less.
[3] Precise Image is currently not available for pediatrics.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

GlobeNewswire Distribution ID 1000810374

Nyxoah Reports First Quarter 2023 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports First Quarter 2023 Financial and Operating Results

Mont-Saint-Guibert, Belgium – May 16, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2023.

Recent Financial and Operating Highlights

  •  Completed all 115 implants in the DREAM U.S. pivotal trial, with 12-month data expected in the first quarter of 2024.
  •  Initiated the modular PMA submission with the filing of the first module.
  •  Submitted 12-month data1 on the first 34 DREAM patients as a late-breaking abstract to SLEEP 2023 demonstrating a 65% AHI responder rate, a 76% ODI responder rate and safety in-line with expectations. The abstract will be presented in a late-breaking poster session on June 6th. These data are preliminary and not conclusive of final DREAM success.
  •  Implanted the first patients in the ACCCESS U.S. IDE pivotal study to treat complete concentric collapse (CCC). Implant completion expected in 2024.
  •  Hired Christoph Eigenmann as Chief Commercial Officer.
  •  Raised €19 million from new and historical shareholders including ResMed, Cochlear and Robert Taub, Nyxoah’s Chairman and Founder.
  •  Ended the quarter with 40 active German accounts and quarterly sales of €441 thousand.
  •  Expanded European market access with first implants in Austria.
  •  Strengthened the supply chain with the Belgium manufacturing facility receiving clearance from the EU notified body.

“In 2023, our focus is in the U.S. on DREAM patient follow up resulting in reaching the primary endpoints. I am excited by the data on the first 34 patients and look forward to sharing the full abstract results at SLEEP 2023 next month. Our increasing conviction in DREAM outcomes is accelerating investment in our commercial organization, starting with the addition of Christoph as Chief Commercial Officer,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “Christoph’s hire, along with the €19 million raised from key investors, puts us in a strong position as we embark on our next stage of growth.”

First Quarter 2023 Results

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION – CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2023  (in thousands)

        For the three months ended March 31
2023   2022
Revenue €441 €660
Cost of goods sold   (175) (289)
Gross profit €266 €371
Research and Development Expense   (6,157) (3,595)
Selling, General and Administrative Expense (5,551) (4,193)
Other income/(expense) 46 136
Operating loss for the period   €(11,396) €(7,281)
Financial income 625 1,576
Financial expense   (958) (788)
Loss for the period before taxes €(11,729) €(6,493)
Income taxes   (182) (208)
Loss for the period €(11,911) €(6,701)
     
Loss attributable to equity holders €(11,911) €(6,701)
Other comprehensive loss  
Items that may be subsequently reclassified to profit or
loss (net of tax)
Currency translation differences   (28) ( 102)
Total comprehensive loss for the year, net of tax €(11,939) €(6,803)
Loss attributable to equity holders   €(11,939) €(6,803)
Basic Loss Per Share (in EUR) €(0.460) €(0.260)
Diluted Loss Per Share (in EUR) €(0.460) €(0.260)

 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION – CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF MARCH 31, 2023 (in thousands)

    As at
March 31
2023
  December 31 2022
ASSETS
Non-current assets      
Property, plant and equipment €2,721 €2,460
Intangible assets 42,447   39,972
Right of use assets 3,669 3,159
Deferred tax asset     50   47
Other long-term receivables 169 173
    €49,056   €45,811
Current assets      
Inventory     1,249   882
Trade receivables 1,499 1,463
Other receivables     1,419   1,775
Other current assets 1,663 1,284
Financial assets 62,403 76,968
Cash and cash equivalents 33,664 17,888
  €101,897 €100,260
Total assets €150,953 €146,071
   
EQUITY AND LIABILITIES
Capital and reserves    
Capital 4,859 4,440
Share premium 243,488   228,275
Share based payment reserve   6,582 5,645
Other comprehensive income 148   176
Retained loss   (130,051) (118,212)
Total equity attributable to shareholders €125,026 €120,324
     
LIABILITIES
Non-current liabilities    
Financial debt 8,381   8,189
Lease liability   3,112 2,586
Pension liability 25  
Provisions   74 59
Deferred tax liability  
€11,592 €10,834
Current liabilities    
Financial debt 390   388
Lease liability   711 719
Trade payables 5,012   4,985
Current tax liability 3,619   3,654
Other payables 4,603   5,167
  €14,335 €14,913
Total liabilities €25,927 €25,747
Total equity and liabilities €150,953 €146,071

Revenue

Revenue was €441,000 for the first quarter ending March 31, 2023, compared to €660,000 for first quarter ending March 31, 2022.

Cost of Goods Sold

Cost of goods sold was €175,000 for the three months ending March 31, 2023, representing a gross profit of €266,000, or gross margin of 60.3%. This compares to total cost of goods sold of €289,000 in the first quarter ending March 31, 2022, for a gross profit of €371,000, or gross margin of 56.2%.

Research and Development Expenses

Research and development expenses were €6.2 million for the three months ending March 31, 2023, versus €3.6 million for the prior year period, driven by an acceleration in clinical activities, notable the start of the ACCCESS study.

Selling, General and Administrative Expenses

Selling, general and administrative expenses rose to €5.6 million for the first quarter of 2023, up from €4.2 million in the first quarter of 2022. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

Operating Loss

Total operating loss for the first quarter 2023 was €11.4 million versus €7.3 million in the first quarter of 2022. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of March 31, 2023, cash and financial assets totaled €96.1 million, compared to €94.9 million on December 31, 2022.  Total cash burn was approximately €4.9 million per month during the first quarter of 2023.

First Quarter 2023 Report
Nyxoah’s financial report for the first quarter of 2023, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation 
Nyxoah will conduct a conference call open to the public today at 10:30pm CET / 4:30pm ET, which will also be webcast. To participate in the conference call, please access the following link to register for a dial-in number: https://edge.media-server.com/mmc/p/imeku8f7

A question-and-answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements 
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313


1 For the trial to be successful, of the 115 patients, at least 63% of patients need to be AHI and ODI responders at the 12-month follow-up.

Attachment

GlobeNewswire Distribution ID 1000810492

Owler Adds Contact Data to Its Sales Intelligence Solution, Owler Max

SAN FRANCISCO, May 16, 2023 (GLOBE NEWSWIRE) — Owler, a Meltwater offering and the world’s most comprehensive community-powered business data and intelligence platform, today has launched a new feature to its sales intelligence solution Owler Max – Contact Data. This feature will provide its subscribers with direct access to reliable contact information of decision-makers of North American companies, making their prospecting journey more seamless and effective.

With over 15 million companies in its database, Owler has been a go-to resource for sales teams to gather insights on companies, their competitors, funding, and leadership changes. Now with Contact Data, sales teams can easily uncover direct phone numbers, email addresses, and LinkedIn profiles of key contacts within an organization in a matter of seconds.

The new feature has been launched in response to the growing demand of sales teams who are constantly looking for ways to enhance their outreach efforts. Owler’s Contact Data feature has been designed to help sales teams save time and optimize their sales process by providing them with the necessary contact details of the decision-makers they are targeting.

Tim Harsch, CEO of Owler said, ‘We are very excited to introduce Contact Data into our Owler Max tool, This is a powerful way to get in touch with potential customers and partners. Our goal has always been to make it easier for companies to grow and succeed, and this new addition to our platform will help our users do just that.”

This latest addition to Owler Max’s suite of tools is also an indication of the company’s continued commitment to innovation and providing our subscribers with the most cutting-edge tools and resources available. Owler Max, with the new Contact Data feature, is poised to become an even more essential tool for businesses looking to expand their reach and boost sales.

Founded in 2011 and acquired by Meltwater in 2021, Owler is the largest crowdsourced company data provider. Owler datasets are proprietary and sourced first-hand, powered by a community of over 5 million global business professionals representing an active business community. Owler Max’s fresh, accurate and exclusive data, not found on any competitor platforms, eliminates time-consuming additional research.

To learn more about Owler Max or schedule a demo, please visit https://corp.owler.com/owlermax.

About Owler

Owler, a Meltwater offering, is the world’s largest community-driven business information and insights platform. Owler provides exclusive firmographic and competitive data on over 15 million private and public businesses, curated from a community of 5 million business professionals. Owler helps professionals outsmart their competition with actionable insights and real-time alerts about the companies that matter to them. To learn more, visit corp.owler.com, call the US number at 1-650-242-9253, or email support at support@owler.com.

Press contact: 
pr@meltwater.com

GlobeNewswire Distribution ID 8840849

Mass General Brigham and Dana-Farber Cancer Institute collaborating with BEEAH Group to advise on a new, patient-centered health care system

Strategic collaboration supports BEEAH in creating Jawaher Boston Medical District in Sharjah, United Arab Emirates

Boston, MA, May 16, 2023 (GLOBE NEWSWIRE) — Mass General Brigham and Dana-Farber Cancer Institute are collaborating with BEEAH Group, an organization pioneering sustainability and quality of life solutions in the Middle East, to advise in the development of the Jawaher Boston Medical District, a state-of-the-art health care system designed to deliver world-class, patient-centered care through innovation, technology, and sustainability. Mass General Brigham and Dana-Farber Cancer Institute are strategic partners, serving in an advisory capacity, on the project in Sharjah, United Arab Emirates, which includes a multi-specialty flagship hospital for integrated, cutting-edge care.

The collaboration combines the depth and breadth of clinical expertise and innovation from Mass General Brigham and Dana-Farber Cancer Institute, with BEEAH’s vision to create a sustainable, advanced, patient-centered health system designed to deliver care to patients within – and beyond – hospital walls. BEEAH Group was founded in 2007 to tackle sustainability challenges in Sharjah and improve quality of life.

Focused on serving the unique needs of the people of Sharjah and the region, the Jawaher Boston Medical District will offer patients access to the latest clinical expertise across a wide variety of integrated clinical specialties, including lifestyle medicine and prevention, oncology, women’s health, pediatrics, cardiovascular, neurosciences, behavioral health, and rehabilitation medicine. In addition to medical and research expertise, Mass General Brigham and Dana-Farber Cancer Institute will also collaborate with BEEAH Group to advise on best practices in workforce training, development, and public education to the community, with attention to developing local talent.

Mass General Brigham and Dana-Farber Cancer Institute are advising BEEAH Group in their development of multiple facilities, comprising the flagship hospital and ambulatory clinics across Sharjah, with integrated, innovative, and digital solutions, including app-based care and hospital-at-home.

“Mass General Brigham has a deep history of global collaboration aimed at serving and improving the lives of patients around the world,” said Raymond W. Liu, MD, Vice President, Mass General Brigham Global Advisory.  “In collaborating with BEEAH, we hope to contribute our decades of expertise to their development of a unique, innovative vision for a health system that builds on medicine’s leading edge, with an eye to the future.”

“Dana-Farber, a world leader in cancer treatment and research, is committed to advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases locally and globally,” said Adam Reich, Vice President of Business Initiatives at Dana-Farber Cancer Institute. “We are pleased to work with BEEAH and extend our expertise to this collaboration as part of our mission to enhance access to expert cancer care and reduce the burden of cancer worldwide.”

By leveraging its expertise in quality-of-life solutions in Sharjah and the Middle East, BEEAH will create a new destination for the health, wellness and quality of life for the people of Sharjah and the region focused on patient outcomes and experience gleaned from a robust academic ecosystem pioneered, developed and refined over two centuries by Mass General Brigham and Dana-Farber Cancer Institute clinicians.

By pooling their combined medical, research and sustainability expertise, Mass General Brigham, Dana-Farber Cancer Institute and BEEAH will develop innovative technologies, diagnostics, delivery models and patient care, ultimately fostering research, directly benefitting patients globally and providing valuable cross-institutional learnings in the United States. The outcome will enable BEEAH to create a comprehensive patient-centered health care system for the people of Sharjah and the UAE, integrating healthcare solutions into homes, schools, workplaces, and communities to help all patients and their families live healthier lives.

“By partnering with Mass General Brigham and Dana-Farber Cancer Institute, BEEAH Group is entering the healthcare industry and adding a new dimension to our purpose of pioneering a sustainable quality of life for the people of Sharjah, the UAE, and beyond,” said Khaled Al Huraimel, Group CEO of BEEAH Group. “Drawing from the expertise of our partners in Boston, we look forward to creating not just an integrated health network, but a future-ready healthcare ecosystem. The Jawaher Boston Medical District will provide patients in Sharjah access to world-class healthcare closer to home, while also serving as a hub for the development of cutting-edge treatments and medical advancement.”

The project draws from Mass General Brigham and Dana-Farber Cancer Institute’s medical and research expertise, as well as BEEAH Group’s experience collaborating and innovating with international partners to create facilities that are sustainable, digitally-enabled and centered around the comfort and convenience of occupants.

Following a meeting of representatives from Mass General Brigham, Dana-Farber Cancer Institute and BEEAH Group, Sheikha Jawaher Al Qasimi, Wife of the Ruler of Sharjah and Chairperson of BEEAH Group, and Meghan Gregonis, United States General Consul in Dubai, the Jawaher Boston Medical District in Sharjah was approved to move forward.

About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit www.massgeneralbrigham.org.

About Dana-Farber Cancer Institute 
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber is the only hospital with a top 4 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.

For more information, please visit www.dana-farber.org.

About BEEAH Group
BEEAH Group is the region’s leading sustainability and digitalisation expert, renowned for ground-breaking environmental innovations and smart solutions for future-ready cities. Recognising sustainability and technology as the pillars of a modern economy, BEEAH Group has invested in a comprehensive, full-circle strategy for the future. BEEAH Group operates in the industries of waste management, renewable energy, technology, consulting, education, transport, real estate and healthcare. Raising the bar for the quality of life in the region, BEEAH Group businesses continue to set industry benchmarks in sustainable, smart solutions and help countries across the region create and execute their roadmap for a socially responsible future. The Group currently operates in the UAE, Egypt and KSA. For more information, please visit www.beeahgroup.com and connect on LinkedInInstagramFacebook and Twitter @beeahgroup

Noah Brown
Mass General Brigham
617-643-3907
Nbrown9@mgb.org

GlobeNewswire Distribution ID 8840712

Zoom Partners with Anthropic to Expand Federated Approach to AI

Zoom announces investment in Anthropic to support research roadmaps and build steerable AI systems; Anthropic’s AI model will help strengthen Zoom’s federated approach across its platform, including Zoom Contact Center integrations

SAN JOSE, Calif., May 16, 2023 (GLOBE NEWSWIRE) — Today, Zoom announced a strategic partnership with and investment in Anthropic, an AI safety and research company working to build reliable, interpretable, and steerable AI systems. The collaboration with Anthropic will further bolster Zoom’s federated approach to AI by allowing Anthropic’s AI assistant, Claude, to be integrated with Zoom’s platform (which includes Team Chat, Meetings, Phone, Whiteboard, Zoom IQ), starting with Zoom Contact Center.

“Anthropic’s Constitutional AI model is primed to provide safe and responsible integrations for our next-generation innovations, beginning with the Zoom Contact Center portfolio. With Claude guiding agents toward trustworthy resolutions and powering self-service for end-users, companies will be able to take customer relationships to another level,” said Smita Hashim, chief product officer for Zoom. “Partnering with Anthropic also furthers our commitment to providing customers with our federated approach to AI, optimized to deliver outstanding customer experience outcomes. Additionally, with our investment, we are advancing leading-edge companies like Anthropic and helping to drive innovation in the Zoom ecosystem and beyond.”

“Partnering with a leading collaboration platform like Zoom allows us to put robust, steerable AI into the hands of more people and unlock its potential to help streamline everyday processes,” said Dario Amodei, CEO and co-founder of Anthropic. “We look forward to working together to showcase Anthropic’s capabilities and our joint commitment to enhancing productivity through intelligent solutions.”

Zoom’s federated approach to AI leverages its own proprietary AI models, along with those from leading AI companies — such as Anthropic — and select customers’ models. With this flexibility to incorporate multiple types of models, Zoom can provide the most value for its customers’ diverse needs. Zoom will be able to customize these models to perform better for a customer, based on their specific business needs.

As the next step in evolving the Zoom Contact Center portfolio, (Zoom Virtual Agent, Zoom Contact Center, Zoom Workforce Management), Zoom plans to incorporate Anthropic AI throughout its suite, improving end-user outcomes and enabling superior agent experiences. The Zoom Contact Center suite of solutions elevates the quality of customer experiences through better self-service and the ability to accurately understand customer intent. It intelligently guides customers to the best resolution, surfaces actionable insights that managers can use to coach their agents, and improves productivity by providing a unified communications and contact center experience. In the near future, Zoom will also use AI to provide the right resources to agents, so customers receive exceptional service experiences regardless of their reason for calling.

Announced today, Zoom Ventures has made an investment in Anthropic, strengthening the relationship between both companies. Anthropic’s research and development aims to create steerable, trustworthy, and responsible large-scale AI systems. Zoom did not disclose the amount of the investment.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Lacretia Taylor
press@zoom.us

GlobeNewswire Distribution ID 8840480

HqO Partners With Savills to Reshape the Workplace of the Future for Corporate Occupiers

HqO is the world’s leading workplace experience platform; Savills is the largest tenant-focused advisory firm in North America

BOSTON, May 16, 2023 (GLOBE NEWSWIRE) —  HqO, the world’s leading workplace experience platform, today announced a strategic partnership with Savills, North America’s largest tenant-focused advisory firm. The partnership will enable Savills to provide its clients the ability to demonstrate the value of real estate through unique, actionable insights into connecting with and empowering employees, increasing flexibility in the workplace, and reimagining how the modern workplace enhances productivity and community.

HqO and Savills – both renowned for their steadfast commitment to advocating for occupiers across the globe, as well as for their cutting-edge technology, market data, and workplace insights – formed the alliance in an effort to best advise corporates navigating a real estate ecosystem that is currently experiencing a generational disruption.

“Savills modern and differentiated approach to translating data and market intelligence into actionable insights for occupiers across the globe, coupled with HqO’s position as a proven leader in the tenant experience space, makes this strategic alliance mutually beneficial for both parties,” said Sarah Dreyer, Executive Vice President, Information, Technology and Digital Strategy at Savills.

Due to the firms’ respective areas of expertise, the partnership will allow Savills and HqO to empirically demonstrate which layouts, amenities, and workplace programs drive employee engagement and maximize the ROI of every dollar spent on office space.

The partnership will provide granular visibility into how employees experience and interact with their workplace. In turn, corporate leaders will be able to evaluate and optimize their office performance to reimagine a modern workplace that enhances productivity, promotes community, and energizes employees.

“The last three years have radically transformed how people connect with each other and the places they work. Being able to activate those trends from users to physical real estate properties is mission-critical today,” said Chase Garbarino, Co-Founder and CEO at HqO. “Savills shares the same vision as HqO, and the overall belief that the future of the workplace will be driven by their experiences. This partnership represents the significant shift in overall mindset towards customer-centricity for the first time in the larger commercial real estate industry.”

About Savills Inc.:
Savills helps organizations find the right solutions that ensure employee success. Sharply skilled and fiercely dedicated, the firm’s integrated teams of consultants and brokers are experts in better real estate. With services in tenant representation, workforce and incentives strategy, workplace strategy and occupant experience, project management, and capital markets, Savills has elevated the potential of workplaces around the corner, and around the world, for 160 years and counting. For more information, please visit Savills.us.

About HqO:
HqO, ranked No. 75 on the Inc. 5000 list, is transforming how people connect with each other and the places they work. The HqO Workplace Experience Platform makes it easy for companies and commercial property teams to create modern workplaces through world-class amenities and services that allow people to thrive and produce the best results. Active in over 250 million square feet in 25 countries, 57% of the Fortune 100 rely on HqO to enhance their workplace experiences, improve employee satisfaction, and drive operational excellence. For more information, visit www.hqo.com.

For additional questions or more information, please reach out to HqOPR@boathouseinc.com.

GlobeNewswire Distribution ID 8840030